Rütter G H
Serapharm Division of Research and Development, Münster, Germany.
J Neurol Neurosurg Psychiatry. 1994 Nov;57 Suppl(Suppl):2-5. doi: 10.1136/jnnp.57.suppl.2.
The increasing use of intravenous immunoglobulin-G preparations (IVIg) calls for evaluation of the requirements for quality and freedom from infection. The WHO Requirements dating from 1982 have been surpassed by the majority of IVIg preparations. Three methods are used for ensuring safety from infection: the restrictive choice of donor, the precise introductory screening of every individual blood or plasma donation, and the additional active virus inactivation procedures that surpass the virus elimination of, for example, the Cohn-fractionation method. Although it is highly improbable that IVIg can transfer infections, this possibility cannot be completely ruled out even when all the GMP (good manufacturing practice) rules are observed most carefully. Increased safety from infection would be provided if blood and plasma donations were obtained nationally from unpaid voluntary donors and if an additional active viral inactivation procedure was introduced.
静脉注射免疫球蛋白G制剂(IVIg)的使用日益增加,这就需要对质量要求和无感染性进行评估。大多数IVIg制剂已经超越了1982年的世界卫生组织要求。有三种方法可确保无感染风险:对献血者进行严格筛选,对每份个体血液或血浆捐献进行精确的初步筛查,以及采用额外的活性病毒灭活程序,这种程序比例如科恩分级分离法的病毒清除效果更好。尽管IVIg极不可能传播感染,但即使最严格地遵守所有GMP(良好生产规范)规则,这种可能性也不能完全排除。如果在全国范围内从不计报酬的自愿献血者那里获取血液和血浆捐献,并且引入额外的活性病毒灭活程序,那么感染安全性将会提高。